Double-boosted protease inhibitor antiretroviral regimens: What role?

Drugs

Volumn 68, Issue 16, 2008, Pages 2257-2267

  Ribera, Esteban ^a   Curran, Adrian ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Atazanavir, therapeutic use; HIV infections, treatment; Lopinavir, therapeutic use; Peptide hydrolase inhibitors, therapeutic use; Ritonavir, therapeutic use; Saquinavir, therapeutic use

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; METABOLISM; MONOTHERAPY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 55149115684     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868160-00001     Document Type: Review

References (58)

1. Bartlett JA, Demas R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001 Jul 27; 15 (11): 1369-77
2. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997 Nov 15; 11 (14): F113-6
3. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004 Jan; 53 (1): 4-9
4. Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002 Jul; 46 (7): 2249-53
5. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000 Aug; 44 (8): 2093-9
6. Dam E, Lebel-Binay S, Rochas S, et al. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Antivir Ther 2007; 12 (3): 371-80
7. la Porte CJ, Wasmuth JC, Schneider K, et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003 Jul 25; 17 (11): 1700-2
8. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004 Feb 20; 18 (3): 503-8
9. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004 Nov; 48 (11): 4256-62
10. Hellinger J, Cohen C, Morris AB, et al. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive individuals. HIV Clin Trials 2005; 6 (2): 107-17
11. Bertz R, Ashbrenner E, Foit C, et al. Assessment of steady-state pharmacokinetics (PK) of three dosing regimens of saquinavir administered as hard gelatin capsules (HGC) in combination with lopinavir/ritonavir (LPV/r) to HIV-infected adults [abstract no. 4.6]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
12. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004 Jun 18; 18 (9): 1291-7
13. von Hentig N, Müller A, Rottmann C, et al. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007 Apr; 51 (4): 1431-9
14. Winston A, Mallon PW, Satchell C, et al. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin Infect Dis 2007 Jun 1; 44 (11): 1475-83
15. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006 May 12; 20 (8): 1131-9
16. Pham PA, Flexner C, Parsons T, et al. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. J Acquir Immune Defic Syndr 2007 Jun 1; 45 (2): 201-5
17. Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther 2006; 11 (1): 53-62
18. Di Giambenedetto S, De Luca A, Villani P, et al. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. HIV Med 2008 Apr; 9 (4): 239-45
19. von Hentig N, Kaykhin P, Stephan C, et al. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrob Agents Chemother 2008 Jun; 52 (6): 2273-5
20. Boffito M, Dickinson L, Hill A, et al. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004 Nov 1; 37 (3): 1376-84
21. Basso S, Solas C, Quinson AM, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. J Acquir Immune Defic Syndr 2002 Sep 1; 31 (1): 115-7
22. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004 Apr 1; 35 (4): 359-66
23. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004 Apr; 75 (4): 310-23
24. Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005 Jan 28; 19 (2): 145-52
25. Corbett AH, Patterson KB, Tien HC, et al. Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2756-61
26. Pham PA, Hendrix CW, Barditch-Crovo P, et al. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir Ther 2007; 12 (6): 963-9
27. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana. Actualizacíon Enero 2008 [online]. Available from URL: http://www.gesida.seimc.org/index.asp [Accessed 2008 Apr 10]
28. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe [online]. Available from URL: http://www.eacs.eu/guide/index.htm [Accessed 2008 Apr 10]
29. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2008 Jan 29: 1-128 [online]. Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 2008 Apr 10]
30. la Porte CJL, Back D, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3: 4-14
31. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS 2003 May 23; 17 (8): 1258-61
32. Schapiro JM. Understanding protease inhibitor potency: the intersection of exposure, efficacy, and resistance. AIDS Read 2001 Jun; 11: 311-5
33. Weinheimer S, Discotto L, Friborg J, et al. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother 2005 Sep; 49 (9): 3816-24
34. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007 Jun 19; 21 (10): 1309-15
35. van der Lugt J, Autar RS, Ubolyam S, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008 May; 61 (5): 1145-53
36. Landman R, Chazallon C, Descamps D, et al. Efficacy and safety of dual-PI regimens for the treatment of ART-naive HIV-1 subjects: 2IP ANRS 127, a randomized pilot study [abstract no. 779]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
37. Ulbricht K, Stoll M, Behrens G, et al. Double protease inhibitor, RTI-sparing therapy regimen in naive HIV-1-infected patients: 24-week virologic response analysis of the LORAN trial [abstract no. 780]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
38. Petersen ML, Wang Y, van der Laan MJ, et al. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 2007 Jul 1; 21 (12): 1547-54
39. Ruiz L, Ribera E, Bonjoch A, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003 Oct 1; 188 (7): 977-85
40. Staszewski S, Babacan E, Stephan C, et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006 Nov; 58 (5): 1024-30
41. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med 2007 Nov; 8 (8): 529-35
42. Gilliam BL, Chan-Tack KM, Qaqish RB, et al. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDS 2006 Nov; 20 (11): 745-59
43. Manosuthi W, Sungkanuparph S, Ruxrungtham K, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2008 Jan 1; 47 (1): 127-9
44. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 Jul 7; 370 (9581): 49-58
45. Nelson M, Arast́eh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005 Dec 1; 40: 404-12
46. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006 Aug 5; 368: 466-75
47. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 Apr 7; 369 (9568): 1169-78
48. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 39-48
49. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 29-38
50. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract no. 792]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
51. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008 Jul 24; 359 (4): 339-54
52. Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008 Apr 1; 47 (4): 429-40
53. Sekar VJ, Lefebvre E, Spinosa-Guzman S, et al. Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and lopinavir/ritonavir [abstract no. 0367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
54. Sekar VJ, Lefebvre E, Mariën K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007 Dec; 29 (6): 795-801
55. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8 (4): 241-8
56. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS 2007 Mar 30; 21 (6): 768-71
57. Martinez-Cajas JL, Wainberg MA. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 2008; 68 (1): 43-72
58. Kosalaraksa P, Bunupuradah T, Engchanil C, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008 Jul; 27 (7): 623-8